Schuster, Anne L. R.
Bollinger, Juli
Geller, Gail
Little, Susan J.
Mehta, Sanjay R.
Sanchez, Travis
Sugarman, Jeremy
Bridges, John F. P.
Funding for this research was provided by:
National Institutes of Mental Health (R01MH124590, R01MH124590, R01MH124590, R01MH124590, R01MH124590, R01MH124590, R01MH124590, R01MH124590)
Burroughs Wellcome Fund (Innovation in Regulatory Science)
Article History
Received: 2 November 2023
Accepted: 17 May 2024
First Online: 29 May 2024
Declarations
:
: The expert stakeholder engagement that guided survey development was deemed non-human subjects research by the Johns Hopkins School of Medicine (JHM #IRB IRB00354016). The survey was deemed non-human subject research by the Ohio State University College of Medicine Institutional Review Board (OSU IRB #2022E1207). As such, explicit informed consent was not required; consent was implied based on individuals’ agreement to participate in the survey.
: Not applicable.
: JS is a member of Merck KGaA’s Ethics Advisory Panel and Stem Cell Research Oversight Committee; a member of IQVIA’s Ethics Advisory Panel; a member of Aspen Neurosciences Clinical Advisory Panel; a member of a Merck Data Monitoring Committee; and a consultant to Biogen. None of these activities are related to the material discussed in this article. SJL receives funding to her institution from Gilead Sciences and served as a consultant to Hookipa Biotech. None of these activities are related to the material discussed in this article. TS has a research grant with ViiV Healthcare, but that research is not related to the material discussed in this article. ALRS, JMB, GG, SRM, JFPB have no disclosures.